Upsher-Smith gets FDA green light for generic Targretin
The Food and Drug Administration has cleared Upsher-Smith Laboratories’ generic version of Valeant Pharmaceutical’s Targretin (bexarotene) capsules. The product is available in 75-mg dosage strength.
Targretin is indicated to treat the skin problems arising from cutaneous T-cell lymphoma, or CTCL, in patients who have not responded well to other treatments.
"This is an exciting time for Upsher-Smith. Our portfolio is more diversified than ever before and we are optimistic that we will continue to grow given the record number of potential ANDA submissions planned over the next several years and key strategic partnerships we've formed," said Rusty Field, Upsher-Smith’s president and CEO, in a press statement.
Targretin is indicated to treat the skin problems arising from cutaneous T-cell lymphoma, or CTCL, in patients who have not responded well to other treatments.
"This is an exciting time for Upsher-Smith. Our portfolio is more diversified than ever before and we are optimistic that we will continue to grow given the record number of potential ANDA submissions planned over the next several years and key strategic partnerships we've formed," said Rusty Field, Upsher-Smith’s president and CEO, in a press statement.